2025-23574NoticeWallet

Rare brain disease MLD now mandatory in newborn screenings nationwide

Published Date: 12/22/2025

Notice

Summary

Great news for newborns and families! Metachromatic Leukodystrophy (MLD), a serious but treatable condition, is now officially added to the list of recommended newborn screenings. Starting soon, health plans must cover this screening with no extra cost, helping catch MLD early and save lives.

Analyzed Economic Effects

2 provisions identified: 2 benefits, 0 costs, 0 mixed.

Employer Plans Must Cover MLD Screening

Non-grandfathered group health plans and group health insurance issuers must cover newborn screening for Metachromatic Leukodystrophy (MLD) without charging copayments, coinsurance, or deductibles for plan years beginning on or after December 16, 2026 (one year after the Secretary accepted the recommendation on December 16, 2025).

RUSP Recommends States Screen Newborns for MLD

The Secretary of HHS accepted HRSA's recommendation on December 16, 2025 to add Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP). The RUSP recommends that every newborn be screened for conditions on the panel, but individual states decide whether and when to add MLD to their state newborn screening programs.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Effective Date
12/22/2025
12/16/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Health Resources and Services Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register